Aurobindo Pharma gets 10 observations from USFDA for its Unit 3 at Hyderabad1 min read . Updated: 04 Jun 2019, 07:07 PM IST
- None of the observations are repetitive and are more procedural in nature, Aurobindo Pharma said
- Shares of Aurobindo Pharma closed at ₹654.10 per scrip on the BSE, down 0.48% from its previous close
New Delhi: Drug firm Aurobindo Pharma on Tuesday said it has received 10 observations from the US health regulator for its Unit 3 in Hyderabad.
Select your Category